Towards More Flexible False Positive Control in Phase III Randomized
  Clinical Trials by Shen, Changyu & Li, Xiaochun
Towards More Flexible False Positive Control in Phase III 
Randomized Clinical Trials 
Changyu Shen1,* and Xiaochun Li2 
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA 
2Department of Biostatistics, Indiana University School of Medicine, Indianapolis, USA 
 
Abstract 
Phase III randomized clinical trials play a monumentally critical role in the evaluation of new 
medical products. Because of the intrinsic nature of uncertainty embedded in our capability in 
assessing the efficacy of a medical product, interpretation of trial results relies on statistical 
principles to control the error of false positives below desirable level. The well-established 
statistical hypothesis testing procedure suffers from two major limitations, namely, the lack of 
flexibility in the thresholds to claim success and the lack of capability of controlling the total 
number of false positives that could be yielded by the large volume of trials.  We propose two 
general theoretical frameworks based on the conventional frequentist paradigm and Bayesian 
perspectives, which offer realistic, flexible and effective solutions to these limitations. Our 
methods are based on the distribution of the effect sizes of the population of trials of interest. The 
estimation of this distribution is practically feasible as clinicaltrials.gov provides a centralized data 
repository with unbiased coverage of clinical trials.  We provide a detailed development of the two 
frameworks with numerical results obtained for industry sponsored Phase III randomized clinical 
trials. 
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1 Introduction 
The conventional statistical hypothesis testing procedure has been widely adopted in biomedical 
research as the foundational framework for study designs and data analyses. Nonetheless, there 
have been continuous criticisms on the p<0.05 criterion as the primary driving force of the 
conclusion of a study. Issues raised in these criticisms include (a) confusion among investigators 
between statistical significance and clinical significance; (b) the incorrect interpretation of lack of 
evidence of effect being equal to evidence of lack of effect for p≥0.05 1; (c) false interpretation of 
p-value being the probability that the null hypothesis is true 2; (d) the universally applied  threshold 
of 0.05 may not be appropriate for all situations 3, 4.  Benjamin et al. proposed to make the statistical 
significance criterion more stringent by changing the threshold from 0.05 to 0.005 to improve 
reproducibility 3. Nevertheless, such a change may cause more confusions in the research 
community on issues (a) and (b).  McShane et al. proposed an alternative solution by demoting p-
value from the predominate piece of evidence to one of many pieces of evidences 4. Nevertheless, 
the authors did not provide specifics on how errors can be controlled or estimated by combining 
different sources of evidence. For example, as conclusions or decision-makings are often 
intrinsically discrete, some thresholds (one way or another) are needed. Yet, there is no discussion 
on how thresholds should be chosen in McShane et al  4.  
Statistical inference of the efficacy of a medical intervention is of paramount importance in 
Phase III randomized clinical trials (RCTs), which represent perhaps the most rigorous clinical 
investigations by any standard with tremendous financial cost. The aforementioned issues with p-
values are of great relevance to how data generated from the huge endeavors devoted to RCTs 
should be interpreted, which has significant public health impact as Phase III RCTs represent the 
last layer of scrutiny before a medical product is put on market to affect a large number of patients. 
Apparently, the threshold for the p-value plays a major role here. In spirit, both Benjamin et al. 3. 
and McShane et al. 4 support the idea that the threshold for p-values should be made different from 
studies to studies to accommodate the specific context of each study. We agree with this view and 
argue that a universally applied threshold is unlikely to work well for all Phase III RCTs. There is 
heterogeneity at different levels among Phase III RCTs. There are scientific, practical and ethic 
factors that could affect how we want to approach the uncertainty of the efficacy of a medical 
intervention. For example, if early phase research demonstrates strong potential in treatment 
efficacy, relaxing the threshold of the p-value for a Phase III trial is justified from the perspectives 
of cost (relaxed threshold means smaller sample size) and ethics (smaller sample size means less 
patients in the control arm).  On the other hand, if a drug has huge number of potential consumers 
(so that false positive has significant impact) and the earlier phase result is not particularly strong, 
then a more stringent threshold may be desirable. 
In this article, we propose two statistical frameworks that allow for flexible false positive 
control for each individual Phase III RCT and in the meanwhile control for the expected number 
of false positives (ENFPs) yielded from the totality of trials in a given period. The first framework 
is based on the currently well-adopted hypothesis testing procedure. The second framework is built 
on a Bayes perspective. We believe these methods are effective solutions to issue (d) discussed at 
the beginning of this section. The second framework has two extra advantages. First, it provides a 
direct assessment on the magnitude of the efficacy with a continuous scale of uncertainty through 
the posterior probability, as opposed to the conventional p-value that cannot be directly interpreted 
as an uncertainty measure on the magnitude of efficacy. This advantage effectively avoids issues 
(a)-(c). As this article is focused on hypothesis testing, we refer interested readers to Shen 5 for 
more details on this aspect. Second, as the posterior probability of null hypothesis being true is a 
monotone function of the Z statistic 6 and consequently a monotone function of the p-value, the 
threshold can be executed at the scale of the posterior probability, which can be more interpretable.  
Central to our strategy is the distribution of the effect size of recently completed Phase III 
RCTs as a prior distribution. The focus on effect size and Bayesian perspective are also proposed 
recently as solutions for the improvement of statistical inference 7.   In a previous study, we have 
demonstrated how this distribution can be estimated using trials registered at clinicaltrials.gov 
(CT.gov) 8. In what follows, we introduce the notations and describe the first framework based on 
the widely adopted statistical hypothesis testing paradigm. We then describe the second framework 
from the Bayes perspective. Lastly, we provide some numerical results and conclude the article 
with a discussion.   
2 Method based on frequentist hypothesis testing   
2.1 Notations 
The setup of our framework is similar to a random-effects ANOVA or meta-analysis. We will first 
introduce notation of parameters and statistics for a fixed trial, followed by the extension to a 
population of trials where parameters are considered random. Bold symbols refer to vectors. We 
will use the term intervention to refer to a new medical product being evaluated and control to 
refer to a suitable comparison treatment.  
For a given trial, we will use ߚ to denote an efficacy measure, which is an unknown numerical 
quantity summarizing the efficacy of the intervention relative to the control for a specific endpoint, 
e.g. ߚ can be the logarithm of the odds ratio of mortality of the control arm over the intervention 
arm. As a convention, we assume higher value of ߚ indicates higher efficacy of the intervention. 
As some Phase III RCTs have multiple endpoints and/or multiple comparison groups, we will use 
ࢼ ൌ ሼߚ௜, ݅ ൌ 1,2…݉ሽ to denote the vector of efficacy measures of a trial. For each trial, the failure 
region (࣠ሻ is the set of ࢼ values corresponding to the definition of null efficacy. There are in 
general two types of failure regions: 
Type A: ࣠ ൌ ⋂ ሼߚ௜ ൑ ܿ௜	ሽ௠௜ୀଵ  
 Type B: ࣠ ൌ ⋃ ሼߚ௜ ൑ ܿ௜	ሽ௠௜ୀଵ , 
where ܿ௜ is the threshold deemed appropriate for efficacy measure i.  The two types of failure 
regions cover all typical testing scenarios including superiority trials, non-inferiority trials, 
equivalence trials and their combinations. Note that equivalence trials can be viewed as having 
type B failure region with two ߚ ’s defined the same way except the positions of the two 
comparison arms are switched. By convention, we will call the failure region of a trial with ݉ ൌ 1 
a type B failure region. A trial is a false positive if we claim ࢼ ∈ ࣠ࢉ when in fact ࢼ ∈ ࣠. Let ࡰ be 
the vector of test statistics for the ݉ comparisons. ࣬ is the rejection region in the sample space of 
ࡰ such that we claim	ࢼ ∈ ࣠ࢉ if ࡰ ∈ ࣬. The type I error rate is  ߙ ൌ ܯܽݔࢼ∗∈࣠Prሾࡰ ∈ 	࣬|ࢼ∗ሿ. 
Control of ߙ is through the specification of ࣬, which is adjusted through multiple-comparison 
procedure for ݉ ൐ 1.  Note that ሺ࣠, ࣬, ߙ) is determined by the investigator(s) of a trial. 
Suppose there is a well-defined population of trials, where the rejection regions are such that 
the type I error rates are allowed to be different from trials to trials. This population of trials induce 
a distribution of ሺࢼ,	࣠, ࣬, ߙ), where ሺࢼ,	࣠, ࣬, ߙ) is considered random. For the sake of argument, 
we will view this distribution as an empirical distribution with a large finite number of quadruplets 
(and therefore sufficient granularity) to avoid technicality in defining a random vector with 
variable dimension (ࢼ ) and a random set (࣠ and ࣬). We assume the index of the efficacy measures 
݅ is not informative of the value of the efficacy measure. In other words, ܮሺߚ௜ሻ ൌ ܮ൫ߚ௝൯, ݅ ് ݆, 
where ܮሺܺሻ is the law of ܺ. Let ߨ ൌ Prሾࢼ ∈ ࣠ሿ be the proportion of trials with null efficacy.  
Similarly, ߩ ൌ Prሾߚ ൑ ܿሿ, where ሺߚ, ܿሻ is a randomly selected pair of efficacy measure and the 
corresponding threshold from the pool of pairs generated by the entire population of trials.  The 
expected number of false positives (ENFP) for N trials is defined as  
                                                    ENFP ൌ ܰPrሾࡰ ∈ 	࣬, ࢼ ∈ ࣠ሿ.	                                                 (1) 
2.2 Flexible type I error rate with control on ENFP (m=1) 
When ݉ ൌ 1 for all trials, we can drop the subscript for ߚ and ܿ, 
Prሾࡰ ∈ 	࣬, ߚ ൑ ܿሿ ൌ Prሾߚ ൑ ܿሿPr	ሾࡰ ∈ 	࣬|ߚ ൑ ܿሿ ൑ Prሾߚ ൑ ܿሿܧሾߙ|ߚ ൑ ܿሿ ൌ ߩܧሾߙ|ߚ ൑ ܿሿ. (2)                         
We make the following assumption:  
First Concordance Assumption: ܧሾߙ|ߚ ൑ ܿሿ ൑ ܧሾߙ|ߚ ൐ ܿሿ: the type I error rate control for those 
without efficacy is on average at least as stringent as those with efficacy.  
The first concordance assumption implies that  
ܧሾߙሿ ൌ ߩܧሾߙ|ߚ ൑ ܿሿ ൅ ሺ1 െ ߩሻܧሾߙ|ߚ ൐ ܿሿ ൒ ߩܧሾߙ|ߚ ൑ ܿሿ ൅ ሺ1 െ ߩሻܧሾߙ|ߚ ൑ ܿሿ 
                    ൌ ܧሾߙ|ߚ ൑ ܿሿ. 
Combining equation (2) and the inequality above, we have  
                    ENFP ൌ ܰPrሾࡰ ∈ 	࣬, ࢼ ∈ ࣠ሿ ൑ ܰߩܧሾߙ|ߚ ൑ ܿሿ ൑ ܰߩܧሾߙሿ ൌ ߬.                         (3) 
With an estimate of ߩ (estimation of ߩ is discussed in a later section), ߩො, we can estimate the upper 
bound ߬ by 
                                                                 ߬̂ ൌ ߩො ∑ ߙ௜ே௜ୀଵ ,                                                             (4) 
where ߙ௜ is the type I error rate for trial i. 
Therefore, we can allow different trials to have different type I error rates and are able to 
estimate an upper bound of the ENFP. The only requirement is the first concordance assumption, 
that is, we assign to those trials without efficacy a type I error rate that is on average at least as 
stringent as that of the trials with efficacy.  This assumption is reasonable in practical settings. A 
natural strategy is to relax the threshold for high likelihood of efficacy and tighten the threshold 
for low likelihood of efficacy. The existing evidence on efficacy before a trial starts could come 
from earlier phase study results, knowledge of biological mechanism or efficacy of similar 
products. Although the existing evidence has uncertainty, it is extremely unlikely that the first 
concordant assumption will be violated under this practice. The worst that could happen is perhaps 
there is no difference on average in the type I error rate between those trials with and without 
efficacy, in which case the first concordance assumption still holds.   
2.3 Flexible type I error rate with control on ENFP (m>1 for some trials) 
A more realistic scenario is that the population of trials is composed of trials with variable m.  With 
the same derivation as in (2), we have  
                            Prሾࡰ ∈ 	࣬, ࢼ ∈ ࣠ሿ ൑ Prሾࢼ ∈ ࣠ሿܧሾߙ|ࢼ ∈ ࣠ሿ ൌ ߨܧሾߙ|ࢼ ∈ ࣠ሿ.                      (5) 
With the same spirit as in the first concordance assumption, we can make the following assumption: 
Second Concordance Assumption: ܧሾߙ|ࢼ ∈ ࣠ሿ ൑ ܧሾߙ|ࢼ ∈ ࣠ࢉሿ: the type I error rate for those 
without overall efficacy is at least as stringent as those with overall efficacy.  
With the second concordant assumption, we have  
                                                             ENFP ൑ ܰߨܧሾߙሿ.                                                          (6) 
Let t  indicate the type of a failure region (i.e. ݐ ൌ ܣ, ܤ) and ߨሺ݉, ݐሻ ൌ Pr	ሾࢼ ∈ ࣠|݉, ݐሿ. For 
simplicity, we will assume Prሾߚ ൑ ܿ|݉, ݐሿ ൌ Prሾߚ ൑ ܿሿ ൌ ߩ. In other words, the probability of 
null efficacy does not depend on the type of failure region and number of efficacy measures. If 
this does not hold, then an analysis stratified by ݐ and/or ݉ can be performed (see last paragraph 
of  Section “Implementation”). Then 
  ߨሺ݉, ݐ ൌ ܣሻ ൑ 	ߩ and ߨሺ݉, ݐ ൌ ܤሻ ൑ ݉ߩ	. 
Let ߜሺߩ,݉, ݐ ൌ ܣሻ ൌ ߩ and ߜሺߩ,݉, ݐ ൌ ܤሻ ൌ ݉ߩ.  Then 
                                                  ߨ ൌ ܧሾߨሺ݉, ݐሻሿ ൑ ܧሾߜሺߩ,݉, ݐሻሿ,                                               (7) 
where the expectation is with respect to the distribution of ሺ݉, ݐሻ. Combining (6) and (7) leads to  
ENFP ൑ ߬ ൌ ܰܧሾߜሺߩ,݉, ݐሻሿܧሾߙሿ. 
With an estimate  ߩො, we can estimate ߬ by 
                                               ߬̂ ൌ ଵே ሺ∑ ߜሺߩො,݉௜, ݐ௜ሻே௜ୀଵ ሻሺ∑ ߙ௜ே௜ୀଵ ሻ,                                            (8)           
where  ݉௜ and ݐ௜  are the number of efficacy measures and type of failure region for trial i.        
2.4 Implementation 
Equations (4) and (8) are the basis for the control of ENFP as a global false positive measure while 
in the meanwhile allowing for flexible type I error rate control of individual trials. We first obtain 
ߩො from recent historical data. From a regulatory perspective, we can choose a desirable threshold 
߬଴ within a period of time (e.g. next five years) and set ߬̂  to 0. With each additional trial, ߬̂ will be 
updated accumulatively based on equations (4) and (8) until it reaches ߬଴. In this process, we can 
decide ߙ௜ for trial i based on the specific context as long as the process that generates ߙ௜ does not 
violate the concordance assumptions. Note that  this process also does not require the knowledge 
of  ܰ at the beginning. Apparently, the process of randomly selecting ߙ௜ from some continuous or 
discrete regions in (0,1) or fix ߙ௜ (e.g. current practice) meets the concordance assumptions. 
When ݉ ൌ 1 for all trials, ENFP control can be achieved by requiring ∑ ߙ௜ே௜ୀଵ ൑ ߬଴/ߩො. In 
other words, ߬଴/ߩො can be viewed as the total error that can be spent on trials during the specific 
period of time in a possibly non-uniform manner, e.g. an alpha spending strategy. 
It should be noted that the strategy just described can be implemented in a stratified fashion. 
For example, we can divide trials into different categories according to the nature of the trials (e.g. 
types of diseases, interventions, and efficacy measurements etc.). Within each stratum, we can 
implement the strategy just described with a stratum-specific ߩ. Similarly, we can also divide trials 
based on ݐ and/or ݉ if there is evidence that  Prሾߚ ൑ ܿ|݉, ݐሿ ് ߩ for at least some ݐ and/or ݉. 
Within each stratum, we can control for ENFP and allow flexible type I error control for individual 
trials as long as we can estimate ߩሺݐ,݉ሻ ൌ Prሾߚ ൑ ܿ|݉, ݐሿ within each stratum.  
3 Method based on Bayesian perspective   
3.1 Flexible trial-specific threshold with control on ENFP (m=1) 
The treatment effect β can be consistently estimated by ߚመ  using well-established methods, which 
has a normal distribution (or at least approximately so) in most Phase III trials where sample sizes 
are relatively large. Let ߪ denote the standard error of ߚመ . Usually ߪ is unknown. Nonetheless,  ߪ 
can be replaced by the standard estimator without impact on the inference procedure to be 
discussed in this section 5. Therefore, without loss of generality, we will assume ߪ is known. Let 
ߠ ൌ ሺߚ െ ܿሻ/ߪ so that positive efficacy is equivalent to ߠ ൐ 0.The conventional Z statistic is ܼ ൌ
ሺߚመ െ ܿሻ/ߪ, which is (approximately) normally distributed with mean ߠ and standard deviation 1. 
Therefore, ܼ can be  viewed as a noisy version of ߠ. The vector ࡰ essentially includes the ܼ values 
for the test of each efficacy measure. Apparently, when ݉ ൌ 1, ࡰ ൌ ܼ. But we will continue using 
the notation ࡰ ∈ 	࣬ with the understanding that it means ܼ ൌ ݖ is greater than the critical value 
corresponding to ࣬. 
If we know the distribution of ߠ across the population of trials, ݃ሺߠሻ, we can compute the 
posterior probability of positive efficacy (i.e. ߠ ൐ 0ሻ for a given efficacy measure with ܼ ൌ ݖ as 
           ݄ሺݖሻ ൌ Prሾߠ ൐ 0|ܼ ൌ ݖሿ ൌ ׬ ܫሺߠ ൐ 0ሻ݃ሺߠሻ߶ሺݖ െ ߠሻ݀ߠ / ׬݃ሺߠሻ߶ሺݖ െ ߠሻ݀ߠ,             (9)               
where ߶ሺ∙ሻ is the probability density function of the standard normal distribution. ݄ሺݖሻ has been 
termed as the h-probability to emphasize that ݃ሺߠሻ is based on results of historical trials 6. It 
captures the proportion of trials with positive efficacy among all trials with ܼ ൌ ݖ . The h-
probability can also be viewed as  1 minus the local false discovery rate (FDR) 9. It has been shown 
that ݄ሺݖሻ is a monotone increasing function of ݖ 6 so that rejection regions defined by the p-value, 
ݖ and ݄ሺݖሻ are all equivalent. Note that ݄ሺݖሻ has a unique advantage over the other two measures 
as its interpretation is more sensible, which makes it heuristically a natural choice for the 
determination of the threshold.  
Shen and Li proposed an assumption that allows the use of ݄ሺݖሻ for the estimation of ENFP 6. 
The assumption can be summarized as the following: 
         Pr	ሾࢊ ∈ 	࣬|ߠଵሿ 	൑ Pr	ሾࢊ ∈ 	࣬|ߠଶሿ for any ߠଵ ൑ 0, ߠଶ ൐ 0 and fixed statistic ࢊ.        (10) 
Equation (10) essentially means the rejection region is stochastically smaller for any given trial 
with null efficacy as compared with any given trial with positive efficacy. Assumption (10) implies 
the first concordance assumption but not necessarily vice versa. To see this, note inequality (10) 
means ܵሺ∙ |ߠଵሻ ൑ ܵሺ∙ |ߠଶሻ, where ܵሺ∙ |ߠሻ is the survival function of α given ߠ. Because ܧሺα|ߠሻ ൌ
׬ ܵሺα|ߠሻ ݀ߙ, it follows that ܧሺα|ߠଵሻ ൑ ܧሺα|ߠଶሻ and then ܧሺα|ߠ ൑ 0ሻ ൑ ܧሺα|ߠ ൐ 0ሻ. 
Under (10), it can be shown that Prሾ	ߠ ൑ 0|ܼ ൌ ݖ, ࡰ ∈ ࣬ሿ ൑ Prሾ	ߠ ൑ 0|ܼ ൌ ݖሿ ൌ 1 െ ݄ሺݖሻ 6. 
Then we have   
         ENFP ൌ ܰPrሾࡰ ∈ 	࣬ሿܧሼPrሾ	ߠ ൑ 0|ܼ, ࡰ ∈ ࣬ሿ |ࡰ ∈ ࣬ሽ ൑ ܯܧሼ1 െ ݄ሺܼሻ|ࡰ ∈ 	࣬ሽ ൌ ߱,  
where  ܯ ൌ ܰPrሾࡰ ∈ 	࣬ሿ is the expected number of positive trials. Then we can use the following 
estimator to estimate the upper bound of ENFP 
                                                        ෝ߱ ൌ 	∑ ሺ1 െ ෠݄ሺݖ௜ሻ௜∈௉ ሻ,                                                        (11) 
where ܲ  is the set of positive trials, ݖ௜  is the observed Z value for trial ݅ ∈ ܲ  , and ෠݄ሺݖ௜ሻ  is 
computed by plugging an estimate ො݃ሺߠሻ in equation (9). The advantage of (11) over (4) is that 
estimator in (11) can be closer to ENFP than (4) because it accounts for the actual negative value 
of ߠ instead of assuming  ߠ ≡ 0 for trials with null efficacy. 
Shen and Li 6 also pointed out that the definition of ENFP in equation (1) averages over all 
possible values of  ࢆ that is composed of the N  Z statistics. Nonetheless, we only observe one 
realization of these Z values in reality.  Thus, the definition of ENFP in equation (1) may not be 
very “relevant”. We may want to consider an alternative definition of ENFP that is conditional on 
the observed ݖ  in the set of positive trials.  A natural way to quantify the propensity of the 
intervention being a false positive is  Prሾߠ ൑ 0|ܼ ൌ ݖ, ࡰ ∈ ࣬ሿ. The computation of Prሾߠ ൑ 0|ܼ ൌ
ݖ,ࡰ ∈ ࣬ሿ requires knowledge of ݃ሺߠ|	ࡰ ∈ ࣬), which is more difficult to estimate than ݃ሺߠሻ for 
two reasons. First, there are fewer historical positive trials compared with the whole collection of 
historical trials, reducing estimation precision. Second, the rejection region can be constantly 
changing once the flexible error control strategy is implemented. Thus, the estimate from history 
may not reflect the presence. As an alternative, we can use 1 െ ݄ሺݖሻ as a measure of propensity of 
false positive.  Along this line, we propose a third concordance assumption that is weaker than (10) 
(e.g. the third concordance assumption holds if (10) is true but not necessarily vice versa 6). 
Third Concordance Assumption: Prሾߠ ൑ 0|ܼ ൌ ݖ,ࡰ ∈ ࣬ሿ ൑ Prሾߠ ൑ 0|ܼ ൌ ݖ, ࡰ ∈ ࣬௖ሿ for all ݖ 
such that there is non-zero density on the set	ሼܼ ൌ ݖ,ࡰ ∈ ࣬ሽ and ሼܼ ൌ ݖ,ࡰ ∈ ࣬௖ሽ, the probability 
of null efficacy among positive trials is no more than that of the negative trials within trials with 
ܼ ൌ ݖ. 
Under the third concordance assumption, we have  
                        Prሾߠ ൑ 0|ܼ ൌ ݖ,ࡰ ∈ ࣬ሿ ൑ Prሾߠ ൑ 0|ܼ ൌ ݖሿ ൌ 1 െ ݄ሺݖሻ.                            (12) 
Therefore, we can use 1 െ ݄ሺݖሻ as a more conservative quantification of the propensity of null 
efficacy given ܼ ൌ ݖ. Below we define an alternative version of ENFP by fixing the observed Z 
values in the set P that is composed of the positive trials, i.e. ࢠ௉ ൌ ሼݖ௜: ݅ ∈ ܲሽ: 
                       ENFP௖௢௡ௗሺࢠ௉ሻ ൌ ∑ Prሾߠ௜ ൑ 0|ܼ௜ ൌ ݖ௜ሿ௜∈௉ ൌ ∑ ൫1 െ ݄ሺݖ௜ሻ൯௜∈௉ .                    (13) 
Inequality (12) implies  
     ܧሺ1 െ ݄ሺܼ௜ሻ|ࡰ࢏ ∈ ࣬࢏ሻ ൒ ࡱሼPrሾߠ௜ ൑ 0|ܼ௜ ൌ ݖ௜, ࡰ࢏ ∈ ࣬࢏ሿ|ࡰ࢏ ∈ ࣬࢏ሽ ൌ Prሾߠ௜ ൑ 0|ࡰ࢏ ∈ ࣬࢏ሿ, 
which means the definition of ENFP௖௢௡ௗሺࢠ௉ሻ in (13) is conservative. The estimator in (11) can be 
directly used for the estimation of ENFP௖௢௡ௗሺࢠ௉ሻ. 
  The execution of the flexible error control from the Bayes perspective is similar to what is 
described previously for the frequentist method. For a trial, we can define ࣬ based on early phase 
efficacy evidence and other factors related to efficacy assessment, e.g. less stringent ࣬  for 
interventions with stronger evidence. Once data are collected we add 1 െ ෠݄ሺݖሻ to ෝ߱ in (11) if ࡰ ∈
࣬. Therefore, for trials with the same ݖ, those deemed positive are the ones with a relaxed ࣬ as 
the result of some evidence of efficacy from other perspectives. According to the third concordance 
assumption, these trials should be at least not more likely to have null efficacy as compared with 
the ones deemed negative (because of a stringent ࣬) that have less evidence of efficacy from other 
perspectives. Certainly, strong early phase result could be generated by large error, in which case 
the actual efficacy may not be that strong (or regression to the mean). Nevertheless, it is extremely 
unlikely that using this kind of evidence to determine rejection region will lead to a violation of 
the third concordance assumption. Trivial cases are very small or large ݖ, where all trials with that 
value will be deemed negative or positive. 
3.2 Flexible trial-specific threshold with control on ENFP (m>1 for some trials) 
Suppose ߠሺ௝ሻ	and ܼሺ௝ሻ ሺ݆ ൌ 1,2… ,݉ሻ are the effect size and Z statistic corresponding to the jth 
efficacy measure. For type A failure region, the event “ߠሺଵሻ ൑ 0” has equal or higher probability 
than the  event ࢼ ∈ ࣠ . Thus, we can consider Prሾߠሺଵሻ ൑ 0|ܼሺଵሻ ൌ ݖሺଵሻ, ࡰ ∈ ࣬, ݐ ൌ ܣ,݉ሿ  as a 
conservative measure of the propensity of null efficacy for a positive trial. For type B failure region, 
we can consider ∑ Prሾߠሺ௝ሻ ൑ 0|ܼሺ௝ሻ ൌ ݖሺ௝ሻ, ࡰ ∈ ࣬, ݐ ൌ ܤ,݉ሿ௠௝ୀଵ . We make the following 
assumption: 
Fourth Concordance Assumption:  
Prൣߠሺ௝ሻ ൑ 0หܼሺ௝ሻ ൌ ݖ, ࡰ ∈ ࣬, ݐ,݉൧ ൑ Prൣߠሺ௝ሻ ൑ 0หܼሺ௝ሻ ൌ ݖ,ࡰ ∈ ࣬௖, ݐ,݉൧  for all ݐ , ݉ , 1 ൑ ݆ ൑
݉  and ݖ  such that there is non-zero density on the set 	൛ܼሺ௝ሻ ൌ ݖ,ࡰ ∈ ࣬, ݐ,݉ൟ,  and ሼܼሺ௝ሻ ൌ
ݖ,ࡰ ∈ ࣬௖, ݐ,݉ሽ: for all ݐ, ݉,	1 ൑ ݆ ൑ ݉ and ݖ , the probability of null efficacy for the jth efficacy 
measure from positive trials is no more than that from the negative trials among  trials with failure 
region ݐ, ݉ efficacy measures and ܼሺ௝ሻ ൌ ݖ. 
        Under the fourth concordance assumption, we have 
Prൣߠሺ௝ሻ ൑ 0หܼሺ௝ሻ ൌ ݖ, ࡰ ∈ ࣬, ݐ,݉൧ ൑ Prൣߠሺ௝ሻ ൑ 0หܼሺ௝ሻ ൌ ݖ, ݐ,݉൧. 
Thus, we can use Prሾߠሺଵሻ ൑ 0|ܼሺଵሻ ൌ ݖሺଵሻ, ݐ ൌ ܣ,݉ሿ or ∑ Prሾߠሺ௝ሻ ൑ 0|ܼሺ௝ሻ ൌ ݖሺ௝ሻ, ݐ ൌ ܤ,݉ሿ௠௝ୀଵ  
to conservatively quantify the propensity of null efficacy for a positive trial with  type A or B 
failure regions. Similar to the counterpart in frequentist hypothesis testing, we will assume the 
distribution of the effect size does not depend on ݐ and/or ݉, i.e. ݃ሺߠ|݉, ݐሻ ൌ ݃ሺߠሻ. Under this 
assumption, the posterior distribution of ߠ does not depend on ݐ and ݉. Therefore, we can further 
simplify the propensity measure to  Prሾߠሺଵሻ ൑ 0|ܼሺଵሻ ൌ ݖሺଵሻሿ  or ∑ Prሾߠሺ௝ሻ ൑ 0|ܼሺ௝ሻ ൌ௠௝ୀଵ
ݖሺ௝ሻሿ .We can then define ENFP௖௢௡ௗሺࢠ௉ሻ as 
ENFP௖௢௡ௗሺࢠ௉ሻ 
ൌ ෍ቐܫሺݐ௜ ൌ AሻPrቂߠ௜ሺଵሻ ൑ 0ቚܼ௜ሺଵሻ ൌ ݖ௜ሺଵሻቃ ൅ ܫሺݐ௜ ൌ Bሻ	෍Prቂߠ௜ሺ௝ሻ ൑ 0ቚܼ௜ሺ௝ሻ ൌ ݖ௜ሺ௝ሻቃ
௠೔
௝ୀଵ
ቑ
௜∈௉
 
ൌ ෍ቐܫሺݐ௜ ൌ Aሻ ቂ1 െ ݄ቀݖ௜ሺଵሻቁቃ ൅ ܫሺݐ௜ ൌ Bሻ෍ቂ1 െ ݄ ቀݖ௜ሺ௝ሻቁቃ
௠೔
௝ୀଵ
ቑ
௜∈௉
 
ൌ ∑ ܩ௜௜∈௉ ,                                                                                                                                  (14) 
where ݖ௜ሺ௝ሻ is the observed Z statistic for the jth efficacy measure of positive trial i. Similar to the 
scenario of m=1, it can be shown that ܧሺܩ௜|	ࡰ࢏ ∈ ࣬࢏ሻ ൒ Pr	ሾࢼ࢏ ∈ ࣠௜|ࡰ࢏ ∈ ࣬࢏ሿ  so that the 
ENFP௖௢௡ௗሺࢠ௉ሻ in (14) is conservative. Similarly to the ݉ ൌ 1 scenario, ENFP௖௢௡ௗሺࢠ௉ሻ can be 
estimated by  
              ෝ߱ ൌ ∑ ቄܫሺݐ௜ ൌ Aሻ ቂ1 െ ෠݄ቀݖ௜ሺଵሻቁቃ ൅ ܫሺݐ௜ ൌ Bሻ∑ ቂ1 െ ෠݄ ቀݖ௜ሺ௝ሻቁቃ௠೔௝ୀଵ ቅ௜∈௉ .                       (15) 
Again, if ݃ሺߠ|݉, ݐሻ ് ݃ሺߠሻ, stratified analysis can be performed separately for each stratum 
defined by ݐ and/or ݉. 
3.3 Implementation 
Equations (11) and (15) are the basis for the implementation of the flexible error control from the 
Bayes perspective. At the beginning of a time period, ෝ߱ is set to 0. For each trial, the rejection 
region can be defined by applying a threshold to the h-probability (equation (9)) for each efficacy 
measure, which can be made different from trials to trials. With each additional positive trial, ෝ߱ 
will be updated accumulatively based on equations (11) and (15) until it reaches a pre-specified 
threshold ߱଴. One advantage of the Bayes method is that it allows for potential adjustment after 
data are collected. For example, suppose there is a costly trial on a target disease population where 
enrollment is very difficult. The trial only reached 75% of the targeted enrollment with a p-value 
short of the pre-specified threshold (e.g. threshold is 0.05 but we got 0.09). There is clearly a 
possibility that the insignificance is caused by insufficient sample size. Unfortunately, the 
conventional frequentist method is incapable of making any adjustment in the decision process to 
address the sample size issue. This is because the alpha has to be determined before data are 
collected. On the other hand, the Bayes method allows us to compute the contribution to the 
number of false positive (e.g. 1 minus h-probability) if we decide to claim it is a positive trial. 
Certainly, such an adjustment could raise concern on the validity of the third or fourth concordance 
assumption as it could “contaminate” the distribution of ߠ in the positive trials (e.g. shifting the 
distribution to the left if the intervention has null efficacy). Nonetheless, as long as the frequency 
of such an adjustment is small, it is unlikely to reverse the relationship of ܧሺܩ௜|	ࡰ࢏ ∈ ࣬࢏ሻ ൒
Pr	ሾࢼ࢏ ∈ ࣠௜|ࡰ࢏ ∈ ࣬࢏ሿ and the estimators (11) and (15) are still conservative.  
4 Estimation of Parameters 
The execution strategies described in previous sections requires estimates of ߩ ൌ Prሾ	ߠ ൑ 0ሿ and 
݃ሺߠሻ. Because ߩ ൌ ׬ ܫሺߠ ൑ 0ሻ݃ሺߠሻ݀ߠ, we can obtain ߩො ൌ ׬ ܫሺߠ ൑ 0ሻ ො݃ሺߠሻ݀ߠ once we obtain 
ො݃ሺߠሻ. If we can collect a representative sample of ܼ values from the underlying population of trials, 
we can then apply deconvolution method  to compute ො݃ሺߠሻ. There is a rich literature on parametric, 
semi-parametric and non-parametric deconvolution methods 10-12. We consider a semi-parametric 
method developed by Efron that strikes a balance between robustness and efficiency 11. 
  Under the Food and Drug Administration Amendments Act (FDAAA), all Phase III clinical 
trials of drugs, medical devices and biologics that were initiated after September 27, 2007, or were 
ongoing as of December 26, 2007 13, are required to be registered at clinicaltrials.gov (CT.gov) 
regardless of trial results. Trials on medical products approved by the Food and Drug 
Administration (FDA) are also required to submit aggregated trial results. This law provides an 
unprecedented opportunity to identify the entire population of  trials and their results, which makes 
the computation of ො݃ሺߠሻ realistic. In a previous study, we identified all Phase III randomized 
superiority trials completed in 2008-2012 that were at least partially sponsored by industry under 
the oversight of the FDA 8. Among the 1393 trials that met our entry criteria, we selected one 
efficacy measure from each trial and sought to identify the p-values through a variety of resources 
including CT.gov, publications, conference abstracts, press release, clinical summary report from 
the sponsor and direct contact of the trial sponsor 8. The reason to resort to other resources beyond 
CT.gov is that  results of trials on medical products not yet approved by the FDA may not be 
reported at CT.gov or results on FDA approved products are not stored at CT.gov due to non-
compliance 14, 15. We were able to retrieve information on the p-values for 1221 efficacy measures 
(88%). We converted the p-values into Z values and estimated ො݃ሺߠሻ using Efron’s deconvolution 
method 8.  For the rest of this section, all results are based on ො݃ሺߠሻ that was estimated on the 
assumption that the 12% trials we could not retrieve p-values on are all negative trials with ݌ ൒
0.05. This assumption is conservative in the sense ො݃ሺߠሻ could be biased to the left if some of the 
12% of trials are indeed positive trials. 
 
Figure 1. ෠݄ሺݖሻ as a function of ݖ based on a conservative estimate of ො݃ሺߠሻ [5]. Dashed lines are 
95% confidence intervals based on 500 bootstrap samples. 
The estimated ො݃ሺߠሻ leads to a ߩො ൌ 9% (95% CI: 6.8-11.1%) 8, suggesting that about one 
efficacy measure out of 10 efficacy measures of the included Phase III RCTs is null. Thus, in the 
setting of frequentist hypothesis testing where ݉ ൌ 1 for all trials, the total error is ߬଴/ߩො ൎ 11߬଴. 
If ߬଴ ൌ 1 for a given period of time (e.g. no more than one expected number of false positive), 
then the total error is 11. With a fixed type I error rate of 2.5% for every trial, it means 440 trials 
should be allowed within the projected period of time. A non-uniform spending of the total error 
could lead to more or less number of trials. Fig 1 shows the ෠݄ሺݖሻ as a function of ݖ, where ෠݄ሺݖሻ is 
the estimated h-probability based on ො݃ሺߠሻ . In particular, the conventional threshold of ݖ ൌ
1.96	(corresponding to two-sided p-value of 0.05) is associated with a h-probability of  0.986 (95% 
CI: 0.983-0.989); threshold of ݖ ൌ 1.65	(corresponding to two-sided p-value of 0.1) is associated 
with a h-probability of  0.975 (95% CI: 0.970-0.981).  
5 Discussions 
In this article, we focus on two major limitations of current statistical inference of Phase III RCTs: 
(i) uniformly applied threshold on test statistics may not suit all scenarios; (ii) there is no existing 
method to control/estimate the number of false positives yielded from the large number of Phase 
III RCTs. We proposed two frameworks to address the two limitations based on the frequentist 
hypothesis testing paradigm and Bayesian perspectives. As an illustrative example, we estimated 
distributional parameters (e.g. ො݃ሺߠሻ) for industry sponsored Phase III  superiority RCTs that can 
be used to execute the proposed strategies. It should be noted that the Bayesian solution can also 
address issues (a)-(c) around the very concept of statistical evidence of the efficacy raised at the 
beginning of the article. Specifically, the posterior probability of non-null 6 and credible region of 
the actual efficacy measure 5 (not discussed in this article) are heuristically more accessible to 
investigators for a good understanding of uncertainty 2. 
Key to the execution of the proposed frameworks is sufficient data for accurate ො݃ሺߠሻ. As 
explained in the previous section, the initial FDAAA does not require trial results to be submitted 
to CT.gov for medical products not approved by FDA 13. This has made results retrieval a 
challenging task for some of the 1,393 trials discussed in the previous section. A predominant 
amount of efforts was devoted to the search of trial results not available on CT.gov in our previous 
study.  The US Department of Health and Human Services, under the designation of FDAAA to 
issue regulations regarding certain statutory provisions, has issued a new rule on September 16, 
2016 16.  Under this new rule, trials on essentially all medical products, regardless of FDA approval, 
are required to report summary results on CT.gov. Thus, the proposed strategies are readily feasible 
with the support of the FDAAA and its expanded rules. In particular, it is conceivable that ݃ሺߠሻ 
may not be static over time, particularly in consideration of trial sponsors’ response to a policy 
that allows for more flexible error control. Therefore, ො݃ሺߠሻ can be regularly updated to incorporate 
results of most recent trials. The execution of such a regular update is realistic with the new rules 
that provide guarantee in data support. 
The bound for ENFP based on the Frequentist framework is conservative (higher) as it assumes 
ߚ ൌ ܿ for a null efficacy trial even in fact ߚ ൏ ܿ, e.g. chance of rejecting the null is higher for ߚ ൌ
ܿ than for ߚ ൏ ܿ. Bayesian framework is less conservative as it accounts for the actual distribution 
of the effect size and subsequently factors in the actual values of those ߚ values less than ܿ. On 
the other hand, the Frequentist framework only relies on  ߩ, which is more stable than ݃ሺߠሻ. For 
instance, once the policy of flexible false positive control is first implemented, trials sponsors will 
respond by changing their strategy on which medical products to be put on Phase III. In addition, 
the sample sizes will change based on the false positive error assigned to them. The first factor 
will affect ߩ but both factors will affect ݃ሺߠሻ. Thus, at the start of the new policy, the ߩො computed 
from historical trials is perhaps a more reliable estimate for the ߩ of the trials under the new policy 
as compared with  ො݃ሺߠሻ as an estimate of ݃ሺߠሻ. Therefore, the Frequentist framework is more 
suitable for the beginning of a new policy. Once the policy is in place for a while and the dynamics 
reaches an equilibrium, the Bayesian framework provides a more accurate error control mechanism. 
A natural question following the development in this article is how to determine the rejection 
region for a trial if it is allowed to be different from trial to trial. As the concordance assumptions 
are the main requirement for our solutions, it is important to hold it true when designing the 
strategy for the determination of the rejection region. We project that the concordance assumptions 
will hold provided that the criteria used to determine the rejection region root in other evidence on 
the efficacy of the medical product being investigated such as earlier phase evidence of efficacy, 
biological plausibility, evidence from similar medical products etc. Even if regression to the mean 
may play a role here (e.g. strong efficacy signal from earlier phase may be due to a large error that 
occurred in thousands of compounds being investigated), it is extremely unlikely that it will render 
the concordant assumptions invalid. There are, however, other factors with unclear indication of 
efficacy of a medical product. For example, the existing treatments available to a specific condition, 
the severity of the disease and its impact on quality of life, the size of the patient population, and 
other factors could affect the perceived public health impact of a new medical product. Whether 
or not these factors should be factored into the equation on the determination of the rejection region 
and if yes how to implement it are certainly subject to debate. Statistically, these factors could 
negatively affect the concordant assumptions, e.g. relaxed rejection region for a new product due 
to lack of existing treatment can work against the concordant assumptions because the fact that 
there is no existing treatment could mean high probability that the new product has no efficacy. 
Therefore, these factors should be studied and weighted carefully to determine their roles in the 
determination of the rejection region. 
In summary, the frameworks proposed in this article have the advantages of flexible false 
positive control for individual trials and control of the overall number of false positives. It also is 
practically feasible because the distributional parameters required for its execution can be readily 
estimated and updated using data at CT.gov. As Phase III RCTs serve as the gold standard to 
evaluate the efficacy of a medical product, its direct impact on public health and advancement in 
biomedical research is profound. Statistical criteria are the driving force of the conclusion of an 
RCT, which speaks for its importance. There has been active debate in the statistical and scientific 
communities on the transition from the well-known rule of “p<0.05” to better strategies. Our 
solutions, in the same spirit, offer an effective solution in the setting of Phase III randomized trials. 
We hope to draw more attention on this topic to ultimately improve the way the data are interpreted 
for randomized clinical trials, both individually and collectively. 
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